BR112019010671A8 - Composições líquidas que compreendem um agente mucoadesivo - Google Patents

Composições líquidas que compreendem um agente mucoadesivo

Info

Publication number
BR112019010671A8
BR112019010671A8 BR112019010671A BR112019010671A BR112019010671A8 BR 112019010671 A8 BR112019010671 A8 BR 112019010671A8 BR 112019010671 A BR112019010671 A BR 112019010671A BR 112019010671 A BR112019010671 A BR 112019010671A BR 112019010671 A8 BR112019010671 A8 BR 112019010671A8
Authority
BR
Brazil
Prior art keywords
liquid compositions
mucoadhesive agent
cough
mucoadhesive
agent
Prior art date
Application number
BR112019010671A
Other languages
English (en)
Other versions
BR112019010671A2 (pt
Inventor
P Mcnally Gerard
Pandey Anuraq
Dave Vipul
Original Assignee
Currahee Holding Company Inc
Johnson & Johnson Consumer Inc
Chenango Zero Llc
Chenango Two Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Currahee Holding Company Inc, Johnson & Johnson Consumer Inc, Chenango Zero Llc, Chenango Two Llc filed Critical Currahee Holding Company Inc
Publication of BR112019010671A2 publication Critical patent/BR112019010671A2/pt
Publication of BR112019010671A8 publication Critical patent/BR112019010671A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

A presente invenção refere-se a composições úteis no tratamento de sintomas de tosse e resfriado, incluindo, mas não se limitando a, tosse, congestão nasal e dor de garganta.
BR112019010671A 2016-11-28 2017-11-28 Composições líquidas que compreendem um agente mucoadesivo BR112019010671A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427080P 2016-11-28 2016-11-28
PCT/US2017/063434 WO2018098470A1 (en) 2016-11-28 2017-11-28 Liquid compositions comprising a mucoadhesive agent

Publications (2)

Publication Number Publication Date
BR112019010671A2 BR112019010671A2 (pt) 2019-10-01
BR112019010671A8 true BR112019010671A8 (pt) 2022-07-26

Family

ID=60766151

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010671A BR112019010671A8 (pt) 2016-11-28 2017-11-28 Composições líquidas que compreendem um agente mucoadesivo

Country Status (7)

Country Link
US (2) US10888620B2 (pt)
EP (1) EP3544631A1 (pt)
CN (1) CN110177542A (pt)
AU (1) AU2017364103C1 (pt)
BR (1) BR112019010671A8 (pt)
CA (1) CA3045118A1 (pt)
WO (1) WO2018098470A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888620B2 (en) * 2016-11-28 2021-01-12 Johnson & Johnson Consumer Inc. Liquid compositions for treating cough or cold symptoms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
AU663857B2 (en) * 1990-10-31 1995-10-26 Procter & Gamble Company, The Dextromethorphan antitussive compositions
FR2674437B1 (fr) 1991-03-29 1993-07-09 Pf Medicament Composition pharmaceutique, utile notamment dans le traitement d'affections gastro-óoesophagiennes.
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
EP1997478B1 (en) 2001-02-15 2013-09-04 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
KR20040084891A (ko) 2001-10-22 2004-10-06 타로 파르마수티컬 인더스트리즈, 엘티디. 미각 차폐용 유출-저항성 제제
US20040185093A1 (en) 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20060062811A1 (en) 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
WO2007110871A2 (en) 2006-03-29 2007-10-04 Naveh Pharma (1996) Ltd. Methods and composition for treating sore throat
JP5548612B2 (ja) 2007-06-05 2014-07-16 カーギル インコーポレイテッド トライボロジー装置を使用した食品の口当たり特性の評価方法
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
WO2013049539A1 (en) * 2011-09-30 2013-04-04 Mcneil-Ppc, Inc. A method of blocking or trapping allergens
US10888620B2 (en) * 2016-11-28 2021-01-12 Johnson & Johnson Consumer Inc. Liquid compositions for treating cough or cold symptoms

Also Published As

Publication number Publication date
US20210093723A1 (en) 2021-04-01
US20180147285A1 (en) 2018-05-31
CN110177542A (zh) 2019-08-27
WO2018098470A1 (en) 2018-05-31
AU2017364103B2 (en) 2023-09-21
RU2019120051A (ru) 2020-12-30
AU2017364103A1 (en) 2019-06-13
RU2019120051A3 (pt) 2021-03-02
AU2017364103C1 (en) 2023-12-21
US11911478B2 (en) 2024-02-27
BR112019010671A2 (pt) 2019-10-01
CA3045118A1 (en) 2018-05-31
US10888620B2 (en) 2021-01-12
EP3544631A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
BR112017006671A2 (pt) composição essencialmente livre de água e que compreende pelo menos um esporo que forma agente de controle biológico fúngico, um poliéter de trisiloxano modificado e sílica fumigada ou precipitada.
EA201791811A1 (ru) Лечение панкреатита
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112015029970A2 (pt) inibidores de cinase
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
EA201800535A1 (ru) Фармацевтические композиции с апремиластом
BR102014031070A2 (pt) método de tratamento de uma formação subterrânea penetrada por um poço, e método para minimizar o sobredeslocamento de um propante a partir de uma formação subterrânea penetrada por um poço
BR112017026125A2 (pt) composições de carbonato de cálcio amorfo para administração por inalação, sublingual ou bucal
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
PE20161498A1 (es) Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion
MX2017002239A (es) Composicion que contiene cineol para la administracion nasal.
CR20180002A (es) Agentes, usos y métodos para el tratamiento
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
ECSP16060194A (es) Formas de dosificación farmacéuticas
BR112019010671A8 (pt) Composições líquidas que compreendem um agente mucoadesivo
BR112017012400A2 (pt) processo para fabricação de partículas de resinato de fenilefrina; partículas de resinato de fenilefrina e uso de partículas de resinato de fenilefrina em formulações farmacêuticas
MX2016009445A (es) Composicion de aminas con olor enmascarado.
CY1119674T1 (el) Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: CHENANGO ZERO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO TWO LLC (US)

B25A Requested transfer of rights approved

Owner name: CURRAHEE HOLDING COMPANY INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)